Sucampo Pharmaceuticals

Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) is a global biopharmaceutical company focused on innovative research and development of proprietary drugs to treat gastrointestinal, ophthalmic and oncology-based inflammatory disorders. Sucampo has a marketed product - AMITIZA® - and a pipeline including lifecycle management and clinical development programs. Sucampo is headquartered in Rockville, Maryland, and has operations in Japan, Switzerland and the United Kingdom.

Company Growth (employees)
Rockville, US
Size (employees)
139 (est)-12%
Sucampo Pharmaceuticals was founded in 1996 and is headquartered in Rockville, US

Sucampo Pharmaceuticals Office Locations

Sucampo Pharmaceuticals has offices in Rockville, Milton, Zug, Kita Ward and in 3 other locations
Rockville, US (HQ)
550 805 King Farm Blvd
Sanda Shi, JP
4 1 Techno Park
Chuo Ward, JP
Kobe Hybrid Business Center, 3rd Floor 6 7 6 Minatojima Minamimachi, Chuo Ku, Kobe City
Chiyoda, JP
Nbf Hibiya Building, 10th Floor 1 1 7 Uchisaiwaicho
Kita Ward, JP
Nishiumeda Mid Building, 4th Floor 2 2 16 Sonezakishinchi
Zug, CH
22 Baarerstrasse

Sucampo Pharmaceuticals Data and Metrics

Sucampo Pharmaceuticals Financial Metrics

Sucampo Pharmaceuticals's revenue was reported to be $230.1 m in FY, 2016 which is a 50% increase from the previous period.

Revenue (FY, 2016)

230.1 m

Revenue growth (FY, 2015 - FY, 2016), %


Gross profit (FY, 2016)

154.1 m

Gross profit margin (FY, 2016), %


Net income (FY, 2016)

18.5 m

EBIT (FY, 2016)

53.9 m

Market capitalization (21-Jul-2017)

680.1 m

Cash (31-Dec-2016)

198.3 m
Sucampo Pharmaceuticals's current market capitalization is $680.1 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016


89.6 m115.5 m153.2 m230.1 m

Revenue growth, %


Cost of goods sold

12.4 m16.3 m36.7 m76 m

Gross profit

77.2 m99.2 m116.4 m154.1 m

Gross profit Margin, %


R&D expense

46.6 m

General and administrative expense

43.8 m

Operating expense total

68 m72 m72 m176.2 m


9.2 m27.2 m44.5 m53.9 m

EBIT margin, %


Interest expense

1.9 m1.5 m6.9 m23.8 m

Interest income

124 k172 k181 k72 k

Pre tax profit

10.3 m27.1 m43.7 m14.4 m

Income tax expense

(3.9 m)(14 m)(10.3 m)4.1 m

Net Income

6.4 m13.1 m33.4 m18.5 m
USDFY, 2013FY, 2014FY, 2015FY, 2016


44.1 m71.6 m108.3 m198.3 m

Accounts Receivable

5.4 m5.3 m22.8 m43 m


4 m3.4 m8.9 m23.5 m

Current Assets

113.4 m122.3 m251.4 m307.2 m


1.2 m763 k6.4 m6.2 m


60.9 m73 m

Total Assets

137 m141.6 m457.2 m520.9 m

Accounts Payable

7.6 m4.1 m11.2 m9.2 m

Current Liabilities

42.6 m33.8 m88.1 m32.4 m

Total Liabilities

353.8 m

Additional Paid-in Capital

72.1 m83.6 m99.2 m120.3 m

Retained Earnings

(27.7 m)(13.7 m)19.6 m38.1 m

Total Equity

58.1 m82.3 m86.4 m167.1 m

Financial Leverage

2.4 x1.7 x5.3 x3.1 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

6.4 m13.1 m33.4 m18.5 m

Depreciation and Amortization

1.5 m10.6 m45.7 m

Accounts Receivable

(4 m)(8.5 m)(18.8 m)


(163 k)(1.4 m)(1.2 m)

Accounts Payable

2.2 m(1.7 m)(2.8 m)

Cash From Operating Activities

(5.4 m)27.5 m18.6 m8.3 m

Purchases of PP&E

(168 k)(3.6 m)(1.2 m)

Cash From Investing Activities

(13.9 m)(131.2 m)(1.8 m)

Cash From Financing Activities

10.6 m149.3 m70.5 m

Interest Paid

156 k6 m20 m
Y, 2016

Financial Leverage

3.1 x

Sucampo Pharmaceuticals Market Value History

Sucampo Pharmaceuticals Online and Social Media Presence

Sucampo Pharmaceuticals Company Life and Culture

You may also be interested in